This is a prospective clinical trial that will examine if biennial contrast-enhanced mammography added to annual 3D mammography (tomosynthesis) substantially improves breast cancer detection with minimal increase in false-positives, in women with a personal history of breast cancer.
The investigators seek to determine if improved breast cancer detection is maintained with biennial contrast-enhanced mammography (CEM) added to annual digital breast tomosynthesis (DBT) with overall fewer false positives than from annual DBT plus CEM. The investigators will offer biennial CEM exams for eligible patients. Enrolled participants will have a baseline CEM exam with their routine DBT exam, and then have another CEM exam 24 months after their baseline CEM exam and then again at 48 months. Participants will continue to have their annual DBT exams during this time as a part of their usual care. Two radiologists (one primary) will evaluate each pair of examinations by sequentially interpreting each of DBT and CEM in opposing order (primary reader DBT then CEM and secondary reader CEM then DBT), initially blinded to the other modality. We expect that with biennial screening, at least a similar number of cancers will be detected with CEM (and possibly more that were occult on the DBT-only screen 12 months prior), with a similar incremental false-positive rate and at least similar (if not improved) overall positive predictive value (PPV1).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
1,500
Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
UPMC Magee-Womens Imaging - Bethel Park
Bethel Park, Pennsylvania, United States
RECRUITINGUPMC Magee at the Lemieux Sports Complex
Cranberry Township, Pennsylvania, United States
RECRUITINGMagee Womancare Monroeville
Monroeville, Pennsylvania, United States
Incremental Cancer Detection Rate
CEM cancer detection rate for first observer vs usual care (annual DBT)
Time frame: at 24 months, 48 months, and 62 months
False-positive recall rate
CEM false-positive findings for first observer vs usual care (annual DBT)
Time frame: at 24 months, 48 months, and 62 months
Positive-predictive values
CEM positive-predictive values for first observer vs usual care (annual DBT)
Time frame: at 24 months, 48 months, and 62 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Magee-Womens Hospital
Pittsburgh, Pennsylvania, United States
RECRUITINGHillman Cancer Center at Shadyside
Pittsburgh, Pennsylvania, United States
RECRUITINGUPMC West Mifflin Outpatient Center
West Mifflin, Pennsylvania, United States
RECRUITING